241 related articles for article (PubMed ID: 29875152)
1. Evidence for the Existence of a CXCL17 Receptor Distinct from GPR35.
Binti Mohd Amir NAS; Mackenzie AE; Jenkins L; Boustani K; Hillier MC; Tsuchiya T; Milligan G; Pease JE
J Immunol; 2018 Jul; 201(2):714-724. PubMed ID: 29875152
[TBL] [Abstract][Full Text] [Related]
2. Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17.
Maravillas-Montero JL; Burkhardt AM; Hevezi PA; Carnevale CD; Smit MJ; Zlotnik A
J Immunol; 2015 Jan; 194(1):29-33. PubMed ID: 25411203
[TBL] [Abstract][Full Text] [Related]
3. GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?
Park SJ; Lee SJ; Nam SY; Im DS
Br J Pharmacol; 2018 Jan; 175(1):154-161. PubMed ID: 29068046
[TBL] [Abstract][Full Text] [Related]
4. What defines a chemokine? - The curious case of CXCL17.
Giblin SP; Pease JE
Cytokine; 2023 Aug; 168():156224. PubMed ID: 37210967
[TBL] [Abstract][Full Text] [Related]
5. Involvement of CXCL17 and GPR35 in Gastric Cancer Initiation and Progression.
Li Y; Liu A; Liu S; Yan L; Yuan Y; Xu Q
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614059
[TBL] [Abstract][Full Text] [Related]
6. The role and clinical significance of the CXCL17-CXCR8 (GPR35) axis in breast cancer.
Guo YJ; Zhou YJ; Yang XL; Shao ZM; Ou ZL
Biochem Biophys Res Commun; 2017 Nov; 493(3):1159-1167. PubMed ID: 28943434
[TBL] [Abstract][Full Text] [Related]
7. CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling.
Giblin SP; Ranawana S; Hassibi S; Birchenough HL; Mincham KT; Snelgrove RJ; Tsuchiya T; Kanegasaki S; Dyer D; Pease JE
Front Immunol; 2023; 14():1254697. PubMed ID: 37942327
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review of chemokine CXC17 (VCC1) in cancer, infection, and inflammation.
Gowhari Shabgah A; Jadidi-Niaragh F; Ebrahimzadeh F; Mohammadi H; Askari E; Pahlavani N; Malekahmadi M; Ebrahimi Nik M; Gholizadeh Navashenaq J
Cell Biol Int; 2022 Oct; 46(10):1557-1570. PubMed ID: 35811438
[TBL] [Abstract][Full Text] [Related]
9. Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα₁₃ and β-arrestin-2.
Jenkins L; Alvarez-Curto E; Campbell K; de Munnik S; Canals M; Schlyer S; Milligan G
Br J Pharmacol; 2011 Feb; 162(3):733-48. PubMed ID: 20958291
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17.
Liu W; Xie X; Wu J
Cell Oncol (Dordr); 2020 Apr; 43(2):311-320. PubMed ID: 31832986
[TBL] [Abstract][Full Text] [Related]
11. CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans.
White CW; Platt S; Kilpatrick LE; Dale N; Abhayawardana RS; Dekkers S; Kindon ND; Kellam B; Stocks MJ; Pfleger KDG; Hill SJ
Sci Signal; 2024 Mar; 17(828):eabl3758. PubMed ID: 38502733
[TBL] [Abstract][Full Text] [Related]
12. GPR35 in Intestinal Diseases: From Risk Gene to Function.
Kaya B; Melhem H; Niess JH
Front Immunol; 2021; 12():717392. PubMed ID: 34790192
[TBL] [Abstract][Full Text] [Related]
13. Activation of the IL-17 signalling pathway by the CXCL17-GPR35 axis affects drug resistance and colorectal cancer tumorigenesis.
Bu J; Yan W; Huang Y; Lin K
Am J Cancer Res; 2023; 13(5):2172-2187. PubMed ID: 37293165
[TBL] [Abstract][Full Text] [Related]
14. Expression and clinical significance of CXCL17 and GPR35 in endometrial carcinoma.
Hao J; Gao X; Wang YP; Liu Q; Zhu H; Zhao SJ; Qin QH; Meng J; Li LL; Lin SC; Song Z; Li H
Anticancer Drugs; 2022 Jun; 33(5):467-477. PubMed ID: 35276691
[TBL] [Abstract][Full Text] [Related]
15. CXCL17: The Black Sheep in the Chemokine Flock.
Denisov SS
Front Immunol; 2021; 12():712897. PubMed ID: 34335630
[No Abstract] [Full Text] [Related]
16. Kynurenic acid and zaprinast diminished CXCL17-evoked pain-related behaviour and enhanced morphine analgesia in a mouse neuropathic pain model.
Rojewska E; Ciapała K; Mika J
Pharmacol Rep; 2019 Feb; 71(1):139-148. PubMed ID: 30550994
[TBL] [Abstract][Full Text] [Related]
17. CXCL17 is a mucosal chemokine elevated in idiopathic pulmonary fibrosis that exhibits broad antimicrobial activity.
Burkhardt AM; Tai KP; Flores-Guiterrez JP; Vilches-Cisneros N; Kamdar K; Barbosa-Quintana O; Valle-Rios R; Hevezi PA; Zuñiga J; Selman M; Ouellette AJ; Zlotnik A
J Immunol; 2012 Jun; 188(12):6399-406. PubMed ID: 22611239
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.
Jenkins L; Brea J; Smith NJ; Hudson BD; Reilly G; Bryant NJ; Castro M; Loza MI; Milligan G
Biochem J; 2010 Dec; 432(3):451-9. PubMed ID: 20919992
[TBL] [Abstract][Full Text] [Related]
19. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor.
Lee WY; Wang CJ; Lin TY; Hsiao CL; Luo CW
Am J Physiol Endocrinol Metab; 2013 Jan; 304(1):E32-40. PubMed ID: 23115081
[TBL] [Abstract][Full Text] [Related]
20. High-throughput identification and characterization of novel, species-selective GPR35 agonists.
Neetoo-Isseljee Z; MacKenzie AE; Southern C; Jerman J; McIver EG; Harries N; Taylor DL; Milligan G
J Pharmacol Exp Ther; 2013 Mar; 344(3):568-78. PubMed ID: 23262279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
